---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-231953"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:36:42.548815+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Board member Dr. Alon Lazarus dies; Werewolf Therapeutics non-compliant with Nasdaq audit committee rule

## Summary
- Dr. Alon Lazarus, board member since Aug 2019, passed away on Sep 30, 2025.
- His death reduced the Audit Committee to two members, violating Nasdaq Rule 5605(c)(2) requiring three members.
- Company notified Nasdaq on Oct 2, 2025; cure period runs until next annual meeting or Sep 30, 2026.
- Board plans to appoint an additional independent director to fill the Audit Committee vacancy.

## SEC filing metadata
- accession: 0001193125-25-231953
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312525231953/0001193125-25-231953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312525231953/d12663d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-231953
- JSON: https://secwatch.observer/filing/0001193125-25-231953.json
- Plain text: https://secwatch.observer/filing/0001193125-25-231953.txt

## Source-grounded claims
- claim_id: fdedabfb675619d8ca755ba56ea8ca128bf2d10e
  claim: Werewolf Therapeutics, Inc. received a nasdaq noncompliance notice notice (rules 5605(c)(2), 5605(c)(4)(B)).
  evidence_excerpt: October 2, 2025, the Company notified Nasdaq of the resulting non-compliance with Nasdaq listing rules caused by Dr. Lazarus’s passing. Pursuant to Nasdaq Listing Rule 5605(c)(4)(B), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2), which cure period will expire upon the earlier of the Company’s next annual meeting of stockholders or September 30, 2026. The Company also informed Nasdaq that the Board plans to regain compliance with the listing rules at its earliest opportunity by appointing an additional independent director of the Company to fi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000119312525231953/0001193125-25-231953-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.